+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of an investigational quadrivalent meningococcal conjugate vaccine called MenACYW compared to locally licensed meningococcal vaccines in healthy infants and toddlers in China. The study focuses on children aged 2 to 23 months and aims to understand how well the vaccine triggers protection against meningococcal infection. This is a Phase 3, randomized, quadruple-blind study conducted to prevent meningococcal infection in this young population. Participants are divided into cohorts based on age groups and receive different vaccine schedules. Cohort I includes children aged 12 to 23 months receiving two doses of MenACYW or the comparator vaccine. Cohort II includes children aged 6 to 11 months receiving two primary doses plus a booster dose for one group. Cohort III includes children aged 2 to 5 months who receive three primary doses plus a booster dose at 12 or 18 months. Blood samples are collected before and after vaccinations to assess immune response, and telephone follow-ups and safety visits are conducted to monitor adverse events and vaccine safety. During the study, participants attend multiple vaccination visits and blood draws at specified days and months after birth, depending on their cohort. Telephone calls are scheduled shortly after each vaccination and monthly for five months following the last visit to check participant health and safety. Researchers measure antibody levels against meningococcal serogroups and track any immediate or delayed adverse reactions. The study duration varies by cohort, lasting from about 7 months to up to 21 months including safety follow-up after the last dose.

Age: 2Months - 23MonthsAll GendersPhase 3
8 locations